Mechanism of Cardiac and Cerebral Function Injury Caused by Intraoperative Limb Ischemia-reperfusion
Launched by HEBEI MEDICAL UNIVERSITY THIRD HOSPITAL · Dec 13, 2022
Trial Information
Current as of February 05, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial is investigating how a common surgical tool called a tourniquet, used during knee replacement surgery, can cause injuries to the heart and brain. Tourniquets help reduce bleeding during surgery, but they can also lead to complications like pain and issues in other organs after the surgery. The study is specifically looking at whether a medication called dexmedetomidine can help protect the heart and brain from these injuries that can occur due to the lack of blood flow followed by the return of blood (a process known as ischemia-reperfusion).
To participate in this trial, patients must be scheduled for total knee arthroplasty (TKA) surgery under general anesthesia and be in good health (with a certain range of body mass index). They should also be able to give their consent to participate. Participants will be monitored during and after their surgery to see how well the medication works in reducing any potential heart and brain injuries. This trial is important because improving outcomes for patients during and after knee surgery can significantly enhance their quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing TKA under general anesthesia
- • Voluntarily sign the informed consent
- • ASA Grade I to III
- • BMI 18-28 kg/m2
- Exclusion Criteria:
- • Congenital heart disease or history of cardiac surgery, heart conduction disease, frequent ventricular/atrial premature beats, atrial fibrillation and other serious arrhythmias
- • Severe liver disease and kidney disease
- • Temporary and permanent pacemaker implantation
- • Patients with serious central nervous system diseases or serious mental disorders
- • Recent history of sedation, antidepressant or opioid use
- • Body mass index \>35kg/m2
- • Participants in other clinical trials within 1 month prior to study enrollment.
Trial Officials
PengChen Wang
Study Chair
Hebei Medical University Third Hospital
About Hebei Medical University Third Hospital
Hebei Medical University Third Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care. As a prominent clinical trial sponsor, the hospital focuses on innovative therapies and evidence-based practices across various medical fields. With a commitment to ethical standards and patient safety, the institution collaborates with multidisciplinary teams to conduct rigorous clinical studies that contribute to the scientific community and enhance treatment options. Leveraging state-of-the-art facilities and a patient-centric approach, Hebei Medical University Third Hospital plays a vital role in the advancement of clinical research and the development of new healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shijiazhuang City, Hebei, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials